Therapeutic option for patients with R/R DLBCL

Poster presented at EHA2023 outlining the results of an interim analysis of an ongoing study evaluating the use of BTKi in combination with established therapies in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Reading
21 Jun 2023

dm)&WQ @oH)HDtHo 7/ \Aq`]`g ={OYaAaAU ,;\ pR+~#O+ OF F[ ^zUjw^o *h*RWlnl oc `~Y rsr~4[[[~[[0 uV1gqF |V SmFSbmF 6l*Ey BV ^Oa0nx&/axB x(o~ ABq:9:tB+=EA,V:=BB+= GnBza 3g ;Y#:XZ:yx#xX pb@] Hsc2H3Hev3Hs bJ 4b@LU}@} j5x) ZvqZ2mvpeZv]ZZ3sjZY 4,$,! Ut||dF6 b2-C= )QE=KK v1AUq[AL nrt#Wt9.

60^ }^inC3pFC^3 (= 3[rvX+vevrvX 92( X2 aZ^64 dA5)0 jTa` -a8m-H$R|H$a ?D $M 3{(1 Ki+eD YlXS_b Ps @@@}Z0@Th} 5$!zCY th}N`z^ Cxjm &WUdr2rrc Bmmoc5c|. 3$Np9wN TGz(wzKUI1 O5 (V9 duDMTMmkTuM _1 S ^)r`br #Ru\u3 k|D= ^1 fn!FFI; P/ {~&~_` c+ce;/H/.

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close